

Appendix C

Sales and cost-effectiveness for globally successful drugs

This appendix lists drugs satisfying the inclusion criteria for Analysis #1:

- Had an available cost-effectiveness ratio
- Achieved market success, defined as global annual sales exceeding \$1 billion within 7 years of the drug's U.S. launch
- Received FDA approval between January 1, 2010, and December 31, 2024

Brand Name	Number (%) of CE ratios exceeding \$150k/QALY	Median CE ratio (per QALY)	Accelerated approval	Reviewed by ICER	ICD range and chapter	Max global sales / year (\$ billion)
Arexvy	0 of 1 (0%)	\$93,981	No	No	A00-B99 Certain infectious and parasitic diseases	\$1.5
Aubagio	0 of 1 (0%)	\$7,115	No	No	G00-G99 Diseases of the nervous system	\$1.9
Brilinta	0 of 1 (0%)	\$40,270	No	No	J00-J99 Diseases of the respiratory system	\$1.1
Cosentyx	0 of 2 (0%)	\$91,787	No	Yes	L00-L99 Diseases of the skin and subcutaneous tissue	\$4.7
COVID-19 Vaccine	0 of 1 (0%)	Less cost, improves health	No	No	A00-B99 Certain infectious and parasitic diseases	\$2.4
Darzalex	0 of 1 (0%)	\$119,216	Yes	No	C00-D48 Neoplasms	\$6.0
Dovato	0 of 1 (0%)	\$22,500	No	No	A00-B99 Certain infectious and parasitic diseases	\$2.8
Dupixent	0 of 2 (0%)	\$106,065	No	Yes	L00-L99 Diseases of the skin and subcutaneous tissue	\$11.6
Eliquis	0 of 4 (0%)	\$13,213	No	No	I00-I99 Diseases of the circulatory system	\$6.4
Enhertu	3 of 5 (60%)	\$220,533	Yes	No	C00-D48 Neoplasms	\$4.1
Entresto	0 of 4 (0%)	\$47,988	No	Yes	I00-I99 Diseases of the circulatory system	\$3.6
Epclusa	1 of 1 (100%)	\$175,355	No	No	A00-B99 Certain infectious and parasitic diseases	\$3.5
Erleada	0 of 1 (0%)	\$68,000	No	Yes	C00-D48 Neoplasms	\$3.0
Eylea	1 of 2 (50%)	\$1,147,293	No	No	H00-H59 Diseases of the eye and adnexa	\$6.3
Fasenra	1 of 1 (100%)	\$371,000	No	Yes	J00-J99 Diseases of the respiratory system	\$1.7
Fluad	1 of 4 (25%)	\$37,700	No	No	J00-J99 Diseases of the respiratory system	\$1.1

Appendix C
Sales and cost-effectiveness for globally successful drugs

Brand Name	Number (%) of CE ratios exceeding \$150k/QALY	Median CE ratio (per QALY)	Accelerated approval	Reviewed by ICER	ICD range and chapter	Max global sales / year (\$ billion)
Hemlibra	0 of 1 (0%)	Less cost, improves health	No	Yes	D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	\$4.7
Ibrance	1 of 1 (100%)	\$843,332	Yes	No	C00-D48 Neoplasms	\$5.4
Ingrezza	1 of 1 (100%)	\$752,080	No	Yes	G00-G99 Diseases of the nervous system	\$1.9
Jardiance	0 of 1 (0%)	\$76,167	No	No	E00-E90 Endocrine, nutritional and metabolic diseases	\$4.0
Kadcyla	1 of 1 (100%)	\$154,915	No	No	C00-D48 Neoplasms	\$1.4
Keytruda	0 of 1 (0%)	\$138,533	Yes	No	C00-D48 Neoplasms	\$14.4
Kisqali	2 of 2 (100%)	\$626,528	No	No	C00-D48 Neoplasms	\$2.1
Lagevrio	0 of 1 (0%)	\$61,000	No	Yes	A00-B99 Certain infectious and parasitic diseases	\$5.7
Lenvima	0 of 1 (0%)	\$33,072	No	No	C00-D48 Neoplasms	\$1.3
Lynparza	1 of 1 (100%)	\$324,116	Yes	Yes	C00-D48 Neoplasms	\$2.3
Mounjaro	0 of 1 (0%)	Less cost, improves health	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$11.5
Nucala	2 of 2 (100%)	\$364,773	No	Yes	J00-J99 Diseases of the respiratory system	\$1.8
Ocrevus	1 of 1 (100%)	\$166,388	No	Yes	G00-G99 Diseases of the nervous system	\$7.1
Opdivo	1 of 3 (33%)	\$94,976	Yes	No	C00-D48 Neoplasms	\$8.0
Paxlovid	0 of 2 (0%)	\$14,966	No	Yes	A00-B99 Certain infectious and parasitic diseases	\$18.9
Perjeta	1 of 1 (100%)	\$472,668	Yes	No	C00-D48 Neoplasms	\$2.8
Repatha	1 of 1 (100%)	\$290,000	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$1.2
Rybelsus	0 of 1 (0%)	Less cost, improves health	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$3.4
Savaysa	0 of 5 (0%)	\$82,224	No	No	I00-I99 Diseases of the circulatory system	\$1.4
Shingrix	0 of 4 (0%)	\$14,889	No	No	A00-B99 Certain infectious and parasitic diseases	\$4.3
Spinraza	1 of 1 (100%)	\$1,112,000	No	Yes	G00-G99 Diseases of the nervous system	\$2.1

Appendix C
Sales and cost-effectiveness for globally successful drugs

Brand Name	Number (%) of CE ratios exceeding \$150k/QALY	Median CE ratio (per QALY)	Accelerated approval	Reviewed by ICER	ICD range and chapter	Max global sales / year (\$ billion)
Tagrisso	2 of 2 (100%)	\$224,279	Yes	No	C00-D48 Neoplasms	\$5.0
Takhzyro	1 of 1 (100%)	\$1,108,000	No	Yes	D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	\$1.5
Taltz	1 of 2 (50%)	\$1,785,659	No	Yes	L00-L99 Diseases of the skin and subcutaneous tissue	\$2.5
Tecfidera	0 of 1 (0%)	Less cost, improves health	No	No	G00-G99 Diseases of the nervous system	\$4.4
Tivicay	0 of 1 (50%)	\$28,250	No	No	A00-B99 Certain infectious and parasitic diseases	\$2.2
Tremfya	1 of 1 (100%)	\$161,000	No	Yes	L00-L99 Diseases of the skin and subcutaneous tissue	\$3.1
Tresiba	0 of 1 (0%)	\$166,644	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$1.5
Trikafta	1 of 1 (100%)	\$1,160,000	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$10.2
Triumeq	0 of 1 (0%)	\$28,250	No	No	A00-B99 Certain infectious and parasitic diseases	\$3.5
Trodelyv	4 of 4 (100%)	\$556,948	Yes	No	C00-D48 Neoplasms	\$1.3
Veklury	1 of 1 (100%)	298,160	No	Yes	A00-B99 Certain infectious and parasitic diseases	\$5.7
Vyndaqel	1 of 1 (100%)	\$880,000	No	No	E00-E90 Endocrine, nutritional and metabolic diseases	\$5.5
Vyvgart	1 of 1 (100%)	\$2,076,000	No	Yes	G00-G99 Diseases of the nervous system	\$2.2
Wegovy	1 of 1 (100%)	\$184,000	No	Yes	E00-E90 Endocrine, nutritional and metabolic diseases	\$8.4
Xgeva	0 of 1 (0%)	\$107,939	No	No	C00-D48 Neoplasms	\$1.7
Xtandi	1 of 1 (100%)	\$437,623	No	No	C00-D48 Neoplasms	\$3.0
Yervoy	1 of 1 (100%)	\$158,139	No	No	C00-D48 Neoplasms	\$1.3
Yescarta	0 of 3 (0%)	\$129,000	No	Yes	C00-D48 Neoplasms	\$1.5
Zolgensma	1 of 1 (100%)	\$243,000	No	Yes	G00-G99 Diseases of the nervous system	\$1.4